



Atty. Dkt. No. 071949-5604

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Buechler et al.
Title: USE OF THROMBUS
PRECURSOR PROTEIN AND
MONOCYTE
CHEMOATTRACTANT
PROTEIN AS DIAGNOSTIC
AND PROGNOSTIC
INDICATORS IN VASCULAR
DISEASES

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.
<u>Vanessa E. Agha</u> (Printed Name)
<u>Vanessa E. Agha</u> (Signature)
<u>3-29-07</u> (Date of Deposit)

Appl. No.: 10/728,067

Filing Date: 12/3/2003

Examiner: Jung

Art Unit: 1641

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment-IDS
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.


A copy of each non-US patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present

04/03/2007 ADDITIONAL 00000013 10028067
01-12-2007
DLMR_299018.1

120-00-00

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/728,067
Filing Date		12/3/2003	
First Named Inventor		Kenneth F. Buechler	
Art Unit		1641	
Examiner Name		Jung, Unsu	
Attorney Docket Number		071949-5604	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US 6,309,888	10-30-2001	Holvoet et al.	
	A2	US 2002/0106708	08-08-2002	Thomas et al.	

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	HEESCHEN et al., "Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban." The Lancet, Vol. 354, pp. 1757-1762, 1999.	
	A4	INDIK and ALPERT, "Detection of pulmonary embolism by D-dimer assays, spiral computed tomography, and magnetic resonance imaging." Progress in Cardiovascular Diseases, Vol. 42, pp 261-272, 2000.	
	A5	KLINE et al., "New diagnostic tests for pulmonary embolism." Annals of Emergency Medicine Vol. 35, pp. 168-180, 2000.	
	A6	SINGH et al., "Optimization technique in human gall bladder health care system." The 1996 IEEE International Conference on Systems, Man and Cybernetics. Part 4 (of 4). Vol. 4, pp 2855-2857, 1996.	
	A7	ZWEIG and CAMPBELL, "Receiver-operating characteristic (ROC) Plots: A fundamental evaluation tool in clinical medicine." Clin. Chem., Vol. 39(4), pp 561-577, 1993.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1-2007		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/728,067
		Filing Date	12/3/2003
		First Named Inventor	Kenneth F. Buechler
		Art Unit	1641
		Examiner Name	Jung, Unsu
Sheet	2	of	2
		Attorney Docket Number	071949-5604


NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A8	Amar <i>et al.</i> , "Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1." <i>J. Hypertens.</i> 24:1083-88, 2006.	
	A9	Beloqui <i>et al.</i> , "Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?" <i>Eur. Heart J.</i> 26:153-58, 2005.	
	A10	Christenson <i>et al.</i> , "Standardization of Cardiac Troponin I Assays: Round Robin of Ten Candidate Reference Materials," <i>Clin. Chem.</i> 47: 431-37, 2001.	
	A11	Deo <i>et al.</i> , "Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis." <i>J. Am. Coll. Cardiol.</i> 44(9): 1812-18, 2004.	
	A12	Hulthe and Fagerberg, "Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR study)." <i>Arterioscler. Thromb. Vasc. Biol.</i> 22: 1162-1167, 2002.	
	A13	Kuller <i>et al.</i> , "Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the cardiovascular health study." <i>Am. J. Epidemiol.</i> 139(12):1164-79, 1994.	
	A14	Naghavi <i>et al.</i> , "From vulnerable plaque to vulnerable patient - Part III: Executive summary of the screening for heart attack prevention and education (SHAPE) task force report." <i>Am. J. Cardiol.</i> , 98(supp): 2H-15H, 2006.	
	A15	Nelson <i>et al.</i> , "Plasma sphingomyelin and subclinical atherosclerosis: Findings from the multi-ethnic study of atherosclerosis." <i>Am. J. Epidemiol.</i> 163:903-12, 2006.	
	A16	Orbe <i>et al.</i> , "Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis." <i>J. Thromb. Haemost.</i> 5: 91-97, 2007.	
	A17	Wang <i>et al.</i> , "Association of C-reactive protein with carotid atherosclerosis in men and women: The Framingham heart study." <i>Arterioscler. Thromb. Vasc. Biol.</i> 22: 1662-1667, 2002.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/728,067
<i>(use as many sheets as necessary)</i>				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	1	of	28	Attorney Docket Number	071949-5604

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	6,156,521		Buechler et al.	12/05/00	
	A2	6,147,688		Clair	11/14/00	
	A3	6,143,576		Buechler	11/07/00	
	A4	6,113,855		Buechler	09/05/00	
	A5	6,019,944		Buechler	02/01/00	
	A6	5,985,579		Buechler et al.	11/16/99	
	A7	5,955,377		Maul et al.	09/21/99	
	A8	5,947,124		Buechler et al.	09/07/99	
	A9	5,939,272		Buechler et al.	08/17/99	
	A10	5,922,615		Nowakowski et al.	07/13/99	
	A11	5,885,527		Buechler	03/23/99	
	A12	5,851,776		Valkirs	12/22/98	
	A13	5,843,690		Gargan	12/01/98	
	A14	5,824,799		Buechler et al.	10/20/98	
	A15	5,795,725		Buechler et al.	08/18/98	
	A16	5,679,526		Buechler et al.	10/21/97	
	A17	5,631,171		Sandstrom et al.	05/20/97	
	A18	5,525,524		Buechler et al.	06/11/96	
	A19	5,480,792		Buechler et al.	01/02/96	
	A20	5,453,359		Gargan	09/26/95	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	EPO	999447A1					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
Examiner Name	Jung				
Attorney Docket Number	071949-5604				
Sheet	2	of	28		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B2	WO	01/16599 A1					

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	Aggarwal et al., "Evaluation of serum lipid profile and cardiac enzyme changes in cerebrovascular accidents," <i>JIMA</i> , 93:331-332 (1995).	
	C2	Akiyama et al., "Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metallo proteinases and Type IV collagen in patients with various types of glomerulonephritis," <i>Res. Commun. In Mol. Path. and Pharm.</i> , 95(2): 115-128 (1997).	
	C3	Albrechtsen, M. and Bock, E. J., "Quantification of Glial Fibrillary Acidic Protein (GFAP) in Human Body Fluids by means of ELISA Employing a Monoclonal Antibody," <i>Neuroimmunol.</i> 8:301-309 (1985).	
	C4	Amaro, A. et al., "Plasma leukocyte elastase concentration in angiographically diagnosed coronary artery disease," <i>Eur. Heart J.</i> 16:615-622 (1995).	
	C5	Ardissino, D. et al., "Tissue-factor antigen and activity in human coronary atherosclerotic plaques," <i>Lancet</i> 349:769-771 (1997).	
	C6	Asano, Y. et al., "Clinical Significance of surfactant protein D as a serum marker of evaluating pulmonary fibrosis in patients with systemic sclerosis," <i>Arthritis Rheum</i> 44(6):1363-9 (June 2001).	
	C7	Austgulen et al., "Increased maternal plasma levels of soluble adhesion molecules (ICAM-1, VCAM-1, E-selectin) in preclampsia," <i>Eur. J. Obstet. Gynecol. Reprod. Biol.</i> , 71:53-58 (1997).	
	C8	Badr-elDin et al., "Eosinophil cationic protein as a serological marker of disease activity in childhood bronchial asthma," <i>East Mediterr. Health J.</i> 5:664-75 (1999).	
	C9	Baker, T. et al., "Serum metalloproteinases and their inhibitors: markers for malignant potential," <i>Br. J. Cancer</i> 70:506-512 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
				Attorney Docket Number	071949-5604
Sheet	3	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C10	Balogopalakrishna, C. <i>et al.</i> , "Modification of low density lipoproteins by erythrocytes and hemoglobin under hypoxic conditions, <i>Adv. Exp. Med. Biol.</i> 411:337-345 (1997).	
	C11	Bandoh <i>et al.</i> , "Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis," <i>Ann. Rheum. Dis.</i> 59:257-62 (2000).	
	C12	Banks <i>et al.</i> , "Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies," <i>Br. J. Cancer</i> 68:122-124 (1993).	
	C13	Bates <i>et al.</i> , "Neurotrophin-3 promotes cell death induced in cerebral ischemia, oxygen-glucose deprivation, and oxidative stress: possible involvement of oxygen free radicals," <i>Neurobiology of Disease</i> 9: 24-37 (2002).	
	C14	Bayes-Genis, A. <i>et al.</i> , "Elevated levels of plasmin- α 2 antiplasmin complexes in unstable angina," <i>Thromb. Haemost.</i> 81:865-68 (1999).	
	C15	Bazzan, M. <i>et al.</i> , "No evidence of platelet activation during atrial pacing in subjects with stable angina," <i>Cardiology</i> 34:217-220 (1989).	
	C16	Benamer <i>et al.</i> , "Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris," <i>Am. J. Cardiol.</i> , 82:845-850 (1998).	
	C17	Bertinchant, J.P. <i>et al.</i> , "Release kinetics of serum cardiac troponin I in ischemic myocardial injury," <i>Clin. Biochem.</i> 29:587-594 (1996).	
	C18	Bialik <i>et al.</i> , "Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53," <i>J. Clin. Invest.</i> 100(6): 1363-1372 (1997).	
	C19	Biasucci <i>et al.</i> , "Episodic activation of the coagulation system in unstable angina does not elicit an acute phase reaction," <i>Am. J. of Cardiol.</i> 77:85-87 (1996).	
	C20	Biasucci, L.M. <i>et al.</i> , "Temporal relation between ischemic episodes and activation of the coagulation system in unstable angina," <i>Circulation</i> 93:2121-2127 (1996).	
	C21	Biasucci <i>et al.</i> , "Elevated levels of interleukin-6 in unstable angina," <i>Circulation</i> 94:874-877 (1996).	
	C22	Biasucci <i>et al.</i> , "Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events," <i>Circulation</i> 99:2079-2084 (1999).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	4	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C23	Bitsch et al., "A longitudinal prospective study of soluble adhesion molecules in acute stroke," <i>Stroke</i> , 29:2129-2135 (1998).	
	C24	Blankaert et al., "Constitutive release of metalloproteinase-9 (92-kd Type IV collagenase) by Kaposi's sarcoma cells," <i>J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.</i> 18:203-209 (1998).	
	C25	Blann et al., "Soluble intercellular adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke," <i>Blood Coagul. Fibrinolysis</i> 10:277-284 (1999).	
	C26	Blann, A.D. et al., "Evidence of platelet activation in hypertension," <i>J. Hum. Hypertens.</i> 11:607-609 (1997).	
	C27	Blann, A.D. et al., "Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers," <i>Thromb. Haemost.</i> 77:1077-1080 (1997).	
	C28	Bonfrer et al., "The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma," <i>Brit. Jour. of Cancer</i> 77(12): 2210-2214 (1998).	
	C29	Bollensen et al., "Adenylate kinase enzyme activity in cases of brain infarction," <i>Acta Neurol. Scand.</i> 79:53-58 (1989).	
	C30	Bonomini, M. et al., "Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients," <i>Nephron</i> 79:399-407 (1998).	
	C31	Bonow, "New insights into the cardiac natriuretic peptides," <i>Circulation</i> 93:1946-1950 (1996).	
	C32	Bossnik et al., "Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis," <i>Blood</i> 86(10): 3841-3847 (1995).	
	C33	Bousquet et al., "Eosinophilic inflammation in asthma," <i>New Engl. J Med.</i> 323:1033-9 (1990).	
	C34	Bowen-Pope, D.F. et al., "Platelet-derived growth factor in vivo: levels, activity, and rate of clearance," <i>Blood</i> 64:458-469 (1984).	
	C35	Brooks and Ergul, "Identification of amino acid residues in the C-terminal tail of big endothelin-1 involved in processing to endothelin-1," <i>J. Mol. Endocrinol.</i> 21:307-15 (1998).	
	C36	Brown, D.L. et al., "Identification of 92-kd gelatinase in human coronary atherosclerotic lesions," <i>Circulation</i> 91:2125-2131 (1995).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	5	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C37	Caligiuri et al., "Immune system activation follows inflammation in unstable angina: pathogenetic implications," <i>J.Am. Coll. Cardiol.</i> 32:1295-1304 (1998).	
	C38	Carlstedt et al., "Proinflammatory cytokines, measured in a mixed population on arrival in the emergency department, are related to mortality and severity of disease," <i>Journal of Internal Medicine</i> 242:361-365 (1997).	
	C39	Carraro, U. and Franceschi, C., "Apoptosis of skeletal and cardiac muscles and physical exercise," <i>Aging (Milano)</i> 9:19-34 (1997).	
	C40	Carter et al., "Platelet GP IIIa P1A and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke," <i>Arterioscler. Thromb. Vasc.</i> 18:1124-1131 (1998).	
	C41	Carter et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," <i>Nature</i> 344:633-638 (1990).	
	C42	Carville, D.G. et al., "Thrombus precursor protein (TpP™): marker of thrombosis early in the pathogenesis of myocardial infarction," <i>Clin. Chem.</i> 42:1537-1541 (1996).	
	C43	Catto et al., "von Willebrand factor and factor VIII: C in acute cerebrovascular disease," <i>Thromb. Haemost.</i> 77:1104-8 (1997).	
	C44	Chong, B.H. et al., "Plasma P-selectin is increased in thrombotic consumptive platelet disorders," <i>Blood</i> 83:1535-1541 (1994).	
	C45	Colucciello, S.A., <i>EMR Textbook</i> , pp. 1-23 http://www.thrombosis-consult.com/articles/Texbook/54_pulmonary , printed 11/04/2002	
	C46	Cohen, A.M. et al., "Plasma clearance and tissue distribution of recombinant human platelet-derived growth factor (B-chain homodimer) in rats," <i>J. Surg. Res.</i> 49:447-452 (1990).	
	C47	Crouch, "Surfactant protein-D and pulmonary host defense," <i>Respir. Res.</i> 1: 93-108 (2000).	
	C48	Curzen et al., "Can C reactive protein or troponins T and I predict outcome in patients with intractable unstable angina?" <i>Heart</i> 80:23-27 (1998).	
	C49	D'Astou, M., "Diastolic Heart Failure," <i>Persp. In Cardiology</i> pp. 30-37 (May 2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
				Attorney Docket Number	071949-5604
Sheet	6	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C50	Dangas et al., "Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease," <i>Am. J. Cardiol.</i> 83:583-585 (1999).	
	C51	Dao et al., "Utility of B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure in an Urgent-Care Setting," <i>J. Am. Coll. Cardiol.</i> 37:379-85 (2001).	
	C52	Davi, G. et al., "Increased levels of soluble P-selectin in hypercholesterolemic patients," <i>Circulation</i> 97:953-957 (1998).	
	C53	Davidson et al., "C-type natriuretic peptide," <i>Circulation</i> 93:1155-9 (1996).	
	C54	Davie et al., "The coagulation cascade: initiation, maintenance and regulation," <i>Biochemistry</i> 30(43): 10363-10370 (1991).	
	C55	De Caterina, R. et al., "Platelet activation in angina at rest. Evidence by paired measurement of plasma beta-thromboglobulin and platelet factor 4*," <i>Eur. Heart J.</i> 9:913-922 (1988).	
	C56	De Rose et al., "Circulating adhesion molecules in cystic fibrosis," <i>Am. J. Respir. Crit. Care Med.</i> 157: 1234-1239 (1998).	
	C57	Depre, C. et al., "Expression of inducible nitric oxide synthase in human coronary atherosclerotic plaque," <i>Cardiovasc. Res.</i> 41:465-472 (1999).	
	C58	Diller, M.P. et al., "Congestive Heart Failure Due to Diastolic or Systolic Dysfunction," <i>Arch Fam Med.</i> 8:414-420 (1999).	
	C59	Dinerman, J.L. et al., "Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction," <i>J. Am. Coll. Cardiol.</i> 15:1559-1563 (1990).	
	C60	Doubell, A.F. et al., "Identification and immunolocalisation of annexins V and VI, the major cardiac annexins, in rat heart," <i>Cardiovasc. Res.</i> 27:1359-1367 (1993).	
	C61	Dunlop, L.C. et al., "Characterization of GMP-140 (P-selectin) as a circulating plasma protein," <i>J. Exp. Med.</i> 175:1147-1150 (1992).	
	C62	Durany, N. and Carreras, J., "Distribution of phosphoglycerate mutase isozymes in rat, rabbit and human tissues," <i>Comp. Biochem. Physiol. B. Biochem. Mol. Biol.</i> 114B:217-223 (1996).	
	C63	Egermayer et al., "Usefulness of D-dimer, blood gas, and respiratory rate measurements for excluding pulmonary embolism," <i>Thorax</i> 53:830-34 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	7	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C64	Eisenberg et al., "Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: evolution of a cytokine control mechanism," <i>Proc. Nat. Acad. Sci. USA</i> , 88: 5232-5236 (1991).	
	C65	Emsley et al., "Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib," <i>Journal of Biological Chemistry</i> 273(17): 10396-10401, (1998).	
	C66	Endo et al., "Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer," <i>Anticancer Research</i> 17:2253-2258 (1997).	
	C67	Endo, S. et al., "Plasma interleukin 8 and polymorphonuclear leukocyte elastase concentrations in patients with septic shock," <i>J. Inflamm.</i> 45:136-142 (1995).	
	C68	Eriksson, S. et al., "Leucocyte elastase as a marker in the diagnosis of acute appendicitis," <i>Eur. J. Surg.</i> 161:901-905 (1995).	
	C69	Ertenli, I. et al., "P-selectin as a circulating molecular marker in rheumatoid arthritis with thrombocytosis," <i>J. Rheumatol.</i> 25:1054-1058 (1998).	
	C70	Estrada et al., "High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke," <i>Am. J. of Hypertension</i> 7(12):1085-1089 (1994).	
	C71	Falciani, M. et al., "Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients," <i>Thromb. Haemost.</i> 79:495-499 (1998).	
	C72	Feinberg et al., "Hemostatic markers in acute ischemic stroke," <i>Stroke</i> 27:1296-1300 (1996).	
	C73	Portales, P.J. et al., "Utility of the serum biochemical markers CPK, CPK MB mass, myoglobin, and cardiac troponin T in a chest pain unit," <i>Rev. Esp. Cardio.</i> 55(9):913-20 (Sep 2002).	
	C74	Fernandes-Alnemri et al., "CPP32, a novel human apoptotic protein with homology to <i>Caenorhabditis elegans</i> cell death protein Ced-3 and mammalian interleukin-1 β -converting enzyme," <i>Journal of Biological Chemistry</i> 269(49): 30761-30764 (1994).	
	C75	Fisher et al., "Serum concentrations and peripheral secretion of the beta chemokines monocyte chemoattractant protein 1 and macrophage inflammatory protein 1 α in alcoholic liver disease," <i>Gut</i> 45(3):416-420 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
				Kenneth F. Buechler	
Group Art Unit				1641	
Examiner Name				Jung	
Attorney Docket Number				071949-5604	

(use as many sheets as necessary)

Sheet	8	of	28
-------	---	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C76	Fon et al., "Hemostatic markers in acute transient ischemic attacks," <i>Stroke</i> 25(2): 282-286 (1994).	
	C77	Forssmann et al., "The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system," <i>Histochem Cell Biol</i> 110: 335-357 (1998).	
	C78	Fox, J.E., "Shedding of adhesion receptors from the surface of activated platelets," <i>Blood Coagul. Fibrinolysis</i> 5:291-304 (1994).	
	C79	Fransen, E.J. et al., "Evaluation of "new" cardiac markers for ruling out myocardial infarction <i>Chest</i> 122(4):1316-21 (Oct 2002).	
	C80	Frijns, C.J. et al., "Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis," <i>Stroke</i> 28:2214-2218 (1997).	
	C81	Fujii et al., "Hemostasis in spontaneous subarachnoid hemorrhage," <i>Neurosurgery</i> 37(2): 226-234 (1995).	
	C82	Fujii et al., "Serial changes of hemostasis in aneurysmal subarachnoid hemorrhage with special reference to delayed ischemic neurological deficits," <i>J. Neurosurg.</i> 86:594-602 (1997).	
	C83	Gaasch, W.H., Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction," <i>JAMA</i> 271:1276-80 (1994).	
	C84	Gabay et al., "Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein," <i>J. Clin. Invest.</i> 99(12): 2930-2940 (1997).	
	C85	Gallino, A. et al., "Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin," <i>Am. Heart J.</i> 112:285-290 (1986).	
	C86	Gamble, J.R. et al., "Prevention of activated neutrophil adhesion to endothelium by soluble adhesion protein," <i>Science</i> 249:414-417 (1990).	
	C87	Gando, S. et al., "Increased neutrophil elastase, persistent intravascular coagulation, and decreased fibrinolytic activity in patients with posttraumatic acute respiratory distress syndrome," <i>J. Trauma</i> 42:1068-1072 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	9	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C88	Garbisa, S. <i>et al.</i> , "Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy," <i>Cancer Res.</i> 52:4548-4549 (1992).	
	C89	Genereau, T. <i>et al.</i> , "Human neutrophil elastase in temporal (Giant Cell) arteritis: plasma and immunohistochemical studies," <i>J. Rheumatol.</i> 25:710-713 (1998).	
	C90	Gensini, G.F. <i>et al.</i> , "Increased protein C and fibrinopeptide: a concentration in patients with angina," <i>Thromb. Res.</i> 50:517-525 (1988).	
	C91	George <i>et al.</i> , "Evidence for altered hepatic matrix degradation in genetic haemochromatosis," <i>Gut</i> 42: 715-720 (1998).	
	C92	Ghaisas, N.K. <i>et al.</i> , "Elevated levels of circulating soluble adhesion molecules in peripheral blood of patients with unstable angina," <i>Am. J. Cardiol.</i> 80:617-619 (1997).	
	C93	Ghanem, H. <i>et al.</i> , "Increased low density lipoprotein oxidation in stable kidney transplant recipients," <i>Kidney Int.</i> 49:488-493 (1996).	
	C94	Giambanco, I. <i>et al.</i> , "Immunohistochemical localization of annexin V (CaBP33) in rat organs," <i>J. Histochem. Cytochem.</i> 39:P1189-1198 (1991).	
	C95	Glatz, J.F. <i>et al.</i> , "Fatty-acid-binding protein as a plasma marker for the estimation of myocardial infarct size in humans," <i>Br. Heart J.</i> 71:135-140 (1994).	
	C96	Gleeson, M. <i>et al.</i> , "The effect of severe eccentric exercise-induced muscle damage on plasma elastase, glutamine and zinc concentrations," <i>Eur. J. Appl. Physiol.</i> 77:543-546 (1998).	
	C97	Gogos <i>et al.</i> , "Pro-versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options," <i>J. Infect. Dis.</i> 181:176-80 (2000).	
	C98	Gohji <i>et al.</i> , "Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma," <i>Cancer</i> 78(11):2379-2387 (12/1/1996).	
	C99	Goldhaber, S.Z., "Modern treatment of pulmonary embolism," <i>Eur. Respir. J. Suppl.</i> 35:22s-27s (2002).	
	C100	Goto <i>et al.</i> , "Enhanced shear-induced platelet aggregation in acute myocardial infarction," <i>Circulation</i> 99:608-613 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
Group Art Unit		1641			
Examiner Name		Jung			
Attorney Docket Number		071949-5604			

(use as many sheets as necessary)

Sheet	10	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C101	Grisolia, S. <i>et al.</i> , "Influence of size, protein concentration, protein synthesis inhibitors, and carbon on clearance of enzymes and proteins from blood," <i>Physiol. Chem. Phys.</i> 8:37-52 (1976).	
	C102	Gruber, B.L. <i>et al.</i> , "Markedly elevated serum MMP-9 (Gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker," <i>Clin. Immunol. Immunopathol.</i> 78:161-171 (1996).	
	C103	Gurfinkel, E. <i>et al.</i> , "Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina," <i>Br. Heart J.</i> 71:151-55 (1994).	
	C104	Hammer-Lercher <i>et al.</i> , "Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosis left ventricular dysfunction," <i>Clin. Chim. Acta</i> 310(2):193-7 (2001).	
	C105	Hammerman, S.I. <i>et al.</i> , "Endothelial cell nitric oxide production in acute chest syndrome," <i>Am. J. Physiol.</i> 277:H1579-H1592 (1999).	
	C106	Hanley and McNeil, "The meaning and use of the area under a receiver operating characteristic (ROC) curve," <i>Radiology</i> 143:29-36 (1982).	
	C107	Harris, "Emergency management of acute asthma," <i>Aust. Fam. Physician</i> 31:802-06 (2002).	
	C108	Hasegawa, S. <i>et al.</i> , "S100a ₀ protein as a marker for tissue damage related to extracorporeal shock wave lithotripsy," <i>Eur. Urol.</i> 24:393-396 (1993).	
	C109	Hasegawa <i>et al.</i> , "Increased levels of calbindin-D in serum and urine from patients treated by extracorporeal shock wave lithotripsy," <i>Journal of Urology</i> 149:1414-1418 (1993).	
	C110	Hayasaka <i>et al.</i> , "Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma," <i>Hepatology</i> 24:1058-1062 (1996).	
	C111	Haznedaroglu, I.C. <i>et al.</i> , "Selectins and IL-6 during the clinical course of idiopathic thrombocytopenic purpura," <i>Acta Haematol.</i> 101:16-20 (1999).	
	C112	Herraez-Dominguez, M.V. <i>et al.</i> , "Immunological determination of muscle-type enolase in the serum as a diagnostic test for myocardial infarction," <i>Clin. Chim. Acta</i> 64:307-315 (1975).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
				Attorney Docket Number	071949-5604
Sheet	11	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C113	Hirashima et al., "Cerebrospinal fluid tissue factor and thrombin-antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage," <i>Stroke</i> 28:1666-1670 (1997).	
	C114	Hirashima et al., "Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage," <i>Neurochem. Res.</i> 22: 1249-1255 (1997).	
	C115	Hoffmeister, H.M. et al., "Alterations of coagulation and fibrinolytic and kallibrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris," <i>Circulation</i> 91:2520-27 (1995).	
	C116	Hoffmeister, H.M. et al., "Correlation between coronary morphology and molecular markers of fibrinolysis in unstable angina pectoris," <i>Atherosclerosis</i> 144:151-157 (1999).	
	C117	Hollander, J.E. et al., "Risk stratification of emergency department patients with acute coronary syndromes using P-selectin," <i>J. Am. Coll. Cardiol.</i> 34:95-105 (1999).	
	C118	Holvoet, P. et al., "Malondialdehyde-modified LDL as a marker of acute coronary syndromes," <i>JAMA</i> 281:1718-21 (1999).	
	C119	Holvoet, P., "Oxidative modification of low-density lipoproteins in atherothrombosis," <i>Acta Cardiol.</i> 53:253-260 (1998).	
	C120	Holvoet, P. et al., "Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease," <i>Circulation</i> 98:1487-94 (1998).	
	C121	Humes, D.H., <i>Kelley's Textbook of Internal Medicine</i> , 4 th Ed., Lippincott Williams & Wilkins, Philadelphia, PA, 2000, pp. 2349-2354, "Approach to the Patient With Dyspnea."	
	C122	Hunt et al., "The amino-terminal portion of Pro-brain natriuretic peptide (pro-BNP) circulates in human plasma," <i>Biochem. Biophys. Res. Commun.</i> 214:1175-1183 (1995).	
	C123	Iiyama, K. et al., "Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation," <i>Circ. Res.</i> 85:199-207 (1999).	
	C124	Iizasa, T. et al., "Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients," <i>Clin. Cancer Res.</i> 5:149-153 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	12	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C125	Ikeda, H. <i>et al.</i> , "Increased soluble form of P-selectin in patients with unstable angina," <i>Circulation</i> 92:1693-1696 (1995).	
	C126	Ikeda, H. <i>et al.</i> , "Soluble form of P-selectin in patients with acute myocardial infarction," <i>Coron. Artery Dis.</i> 5:515-518 (1994).	
	C127	Isgro <i>et al.</i> , "A predictive parameter in patients with brain related complications after cardiac surgery," <i>Eur. J. Cardiothorac. Surg.</i> 11: 640-644 (1997).	
	C128	Ishii, J. <i>et al.</i> , "Serum concentrations of myoglobin vs human heart-type cytoplasmic fatty acid-binding protein in early detection of acute myocardial infarction," <i>Clin. Chem.</i> 43:1372-1378 (1997).	
	C129	Jacque <i>et al.</i> , "Myelin basic protein in CSF and blood," <i>Arch. Neurol.</i> , 39: 557-560, 1982.	
	C130	James, T., "The variable morphological coexistence of apoptosis and necrosis in human myocardial infarction: significance for understanding its pathogenesis, clinical course, diagnosis and prognosis," <i>Coron. Artery Dis.</i> 9:291-307 (1998).	
	C131	Janoff, A., "Elastase in tissue injury," <i>Annu Rev Med</i> 36:207-216 (1985).	
	C132	Jensen <i>et al.</i> , "Characterization of human brain S100 protein fraction: amino acid sequence of S100 β ," <i>J. Neurochem.</i> 45:700-705 (1985).	
	C133	Jimenez, W. <i>et al.</i> , "Nitric oxide production and inducible nitric oxide synthase expression in peritoneal macrophages of cirrhotic patients," <i>Hepatology</i> 30:670-676 (1999).	
	C134	Johnson <i>et al.</i> , "Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques," <i>Arterioscler. Thromb. Vasc. Biol.</i> 18:1707-1715 (1998).	
	C135	Johnsson <i>et al.</i> , "Markers of cerebral ischemia after cardiac surgery," <i>J. Cardiothorac. Vasc. Anesth.</i> 10: 120-126 (1996).	
	C136	Johnston, G.I. <i>et al.</i> , "Structure of the human gene encoding granule membrane protein-140, a member of the selectin family of adhesion receptors for leukocytes," <i>J. Biol. Chem.</i> 265:21381-21385 (1990).	
	C137	Kai, H. <i>et al.</i> , "Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes," <i>J. Am. Coll. Cardiol.</i> 32:368-372 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	13	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C138	Kaikita, K. <i>et al.</i> , "Soluble P-selectin is released into the coronary circulation after coronary spasm," <i>Circulation</i> 92:1726-1730 (1995).	
	C139	Kaikita, K. <i>et al.</i> , "Tissue factor expression on macrophages in coronary plaques in patients with unstable angina," <i>Arterioscler. Thromb. Vasc. Biol.</i> 17:2232-2237 (1997).	
	C140	Kaneko <i>et al.</i> , "Circulating levels of β -chemokines in systemic lupus erythematosus," <i>J. Rheumatol.</i> , 26:568-573 (1999).	
	C141	Kaneko, N. <i>et al.</i> , "Measurement of plasma annexin V by ELISA in the early detection of acute myocardial infarction," <i>Clin. Chim. Acta</i> 251:65-80 (1996).	
	C142	Katayama, M. <i>et al.</i> , "Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome," <i>Br. J. Haematol.</i> 84:702-710 (1993).	
	C143	Kato, K. <i>et al.</i> , "Immunoassay of human muscle enolase subunit in serum: a novel marker antigen for muscle diseases," <i>Clin. Chim. Acta</i> 131:75-85 (1983).	
	C144	Kato, K. and Kimura, "S100a ₀ ($\alpha\alpha$) protein is mainly located in the heart and striated muscles," <i>S., Biochim. Biophys. Acta</i> 842:146-150 (1985).	
	C145	Kaye, D.M. <i>et al.</i> , "The failing human heart does not release nitrogen oxides," <i>Life Sci.</i> 62:883-887 (1998).	
	C146	Keyszer <i>et al.</i> , "Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers," <i>J. Rheumatol.</i> , 26:251-258 (1999).	
	C147	Keyszer, G. <i>et al.</i> , "Matrix metalloproteinases, but not catharsis B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity," <i>Z Rheumatol.</i> 57:392-398 (1998).	
	C148	Kienast, J. <i>et al.</i> , "Prothrombin activation fragment 1 + 2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis," <i>Thromb. Haemost.</i> 70:550-553 (1993).	
	C149	Kikuchi, T. <i>et al.</i> , "Clinical evaluation of serum S100 _{ao} protein in patients with urogenital diseases and healthy volunteers," <i>Hinyokika Kiyo</i> 36:1117-1123 (1990).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
Group Art Unit		1641			
Examiner Name		Jung			
Attorney Docket Number		071949-5604			
(use as many sheets as necessary)					
Sheet	14	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C150	Kim et al., "Cytokines and adhesion molecules in stroke and related diseases," <i>J. Neurol. Sci.</i> , 137:69-78 (1996).	
	C151	Kim et al., "Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist," <i>J. Pharm. Sci.</i> , 84:575-580 (1995).	
	C152	Kim et al., "Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes," <i>J. Immunol.</i> 148:3618-23 (1992).	
	C153	Kobayashi and Kitamura, "KL-6: a serum marker for interstitial pneumonia," <i>Chest</i> 108:311-15 (1995).	
	C154	Kohno, "Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis," <i>J. Med. Invest.</i> 46:151-58 (1999).	
	C155	Koller et al., "Clinical value of monitoring eosinophil activity in asthma," <i>Arch. Dis. Childhood</i> 73:413-7 (1995).	
	C156	Konstantinides S. et al., "Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism," <i>Circulation</i> 106(10):1263-8 (Sept 2002).	
	C157	Kosar, F. et al., "Plasma leukocyte elastase concentration and coronary artery disease," <i>Angiology</i> 49:193-201 (1998).	
	C158	Koukkunen, H. et al., "Troponin T and creatinine kinase isoenzyme MB mass in the diagnosis of myocardial infarction," <i>Ann. Med.</i> 30:488-496 (1998).	
	C159	Koyama et al., "Determination of plasma tissue factor antigen and its clinical significance," <i>Br. J. Haematol.</i> , 87:343-347 (1994).	
	C160	Krause, E.G. et al., "Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction," <i>Mol. Cell Biochem.</i> 160-161:289-295 (1996).	
	C161	Krishnaswamy et al., "Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction," <i>Am. J. Med.</i> 111:274-79 (2001).	
	C162	Kruip, M.J. et al., "Use of a clinical decision rule in combination with D-dimer concentration in diagnostic workup of patients with suspected pulmonary embolism," <i>Arch Intern Med</i> 162(14):1631-5 (7/22/02).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
Group Art Unit		1641			
Examiner Name		Jung			
Attorney Docket Number		071949-5604			

(use as many sheets as necessary)

Sheet	15	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C163	Krupinski, J. et al., "Protein kinase C expression and activity in the human brain after ischaemic stroke," <i>Acta Neurobiol. Exp. (Warz)</i> 58:13-21 (1998).	
	C164	Kruskal, J.B. et al., "Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease," <i>N. Engl. J. Med.</i> 317: 1361-65 (1987).	
	C165	Kudo, S. et al., "Clearance and tissue distribution of recombinant human interleukin 1 β in rats," <i>Cancer Res.</i> 50:5751-5755 (1990).	
	C166	Kurimoto, M. et al., "Plasma platelet-derived growth factor-B chain is elevated in patients with extensively large brain tumour," <i>Acta Neurochir. (Wien)</i> 137:182-187 (1995).	
	C167	Kuwasako et al., "Increased plasma proadrenomedullin N-terminal 20 peptide in patients with essential hypertension," <i>Ann. Clin. Biochem.</i> 36:622-628 (1999).	
	C168	Lai, R.S. et al., "Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion," <i>Jpn J Clin Oncol</i> 29(9):421-4 (Sep 1999).	
	C169	Landi et al., "Hypercoagulability in acute stroke: Prognostic significance," <i>Neurol.</i> , 37:1667-1671 (1987).	
	C170	Laskowitz et al., "Serum markers of cerebral ischemia," <i>J. Stroke Cerebrovasc. Dis.</i> , 7:234-241 (1998).	
	C171	Latini et al., "Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist," <i>J. Cardiovasc. Pharmacol.</i> , 23:1-6 (1994).	
	C172	Laurino, J.P. et al., "Thrombus precursor protein TM and the measurement of thrombosis in patients with acute chest pain syndrome," <i>Ann. Clin. Lab. Sci.</i> 27:338-345 (1997).	
	C173	Lee et al., "Insulin-like growth factors and cerebral ischemia," <i>Ann. N.Y. Acad. Sci.</i> 679:418-422 (1993).	
	C174	Lee et al., "Proteolytic processing of big endothelin-3 by the kell blood group protein," <i>Blood</i> 94:1440-50 (1999).	
	C175	Lein et al., "Metalloproteinasen (MMP-1, MMP-3) and ihre inhibitoren (TIMP) im blutplasma bei patienten mit prostatakarzinom," <i>Urologe [A]</i> 37:377-381 (1998).	
	C176	Li, D. et al., "Acute ischemic heart disease," <i>Am. Heart J.</i> 137:1145-1152 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
				Kenneth F. Buechler	
Group Art Unit				1641	
Examiner Name				Jung	
Attorney Docket Number				071949-5604	

(use as many sheets as necessary)

Sheet	16	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C177	Li et al., "The expression of monocyte chemotactic protein (MCP-1) in human vascular endothelium <i>in vitro</i> and <i>in vivo</i> ," <i>Mol. Cell. Biochem.</i> 126:61-68 (1993).	
	C178	Ling, W. <i>et al.</i> , "Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene," <i>J. Clin. Invest.</i> 100:244-252 (1997).	
	C179	Liras, G. <i>et al.</i> , "Clinical value of an automated granulocyte elastase assay in predicting severity of acute pancreatitis," <i>Rev. Esp. Enferm. Dig.</i> 87:647-652 (1995).	
	C180	Liu et al., "Purification and characterization of an interleukin-1 β -converting enzyme family protease that activates cysteine protease P32 (CPP32)," <i>J. Biol. Chem.</i> 271:13371-13376 (1996).	
	C181	Liuzzo et al., "Plasma protein acute-phase response in unstable angina is not induced by ischemic injury," <i>Circulation</i> 94:2373-2380 (1996).	
	C182	Livrea, M.A. <i>et al.</i> , "Oxidative modification of low-density lipoprotein and atherogenetic risk in β -thalassemia," <i>Blood</i> 92:3936-3942 (1998).	
	C183	Long et al., "p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes," <i>J. Clin. Invest.</i> 99:2635-2643 (1997).	
	C184	Lundergan <i>et al.</i> , "Clinical investigations: acute ischemic heart disease," <i>Am. Heart J.</i> 144:456-62 (2002).	
	C185	MacManus, J.P. <i>et al.</i> , "Cerebral ischemia produces ladder DNA fragments distinct from cardiac ischemia and archetypal apoptosis," <i>J. Cereb. Blood Flow Metab.</i> 19:502-510 (1999).	
	C186	Mahadevan, D. <i>et al.</i> , "Structural role of extracellular domain 1 of α -platelet-derived growth factor (PDGF) receptor for PDGF-AA and PDGF-BB binding," <i>J. Biol. Chem.</i> 270:27595-27600 (1995).	
	C187	Mair, J. <i>et al.</i> , "Early release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterations," <i>Br. Heart J.</i> 72:125-127 (1994).	
	C188	Mair, J., "Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage," <i>Clin. Chim. Acta</i> 272:79-86 (1998).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
(use as many sheets as necessary)				Attorney Docket Number	071949-5604
Sheet	17	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C189	Mair, J., "Progress in myocardial damage detection: new biochemical markers for clinicians," <i>Crit. Rev. Clin. Lab. Sci.</i> 34:1-66 (1997).	
	C190	Mair, P. <i>et al.</i> , "Glycogen phosphorylase isoenzyme BB mass release after coronary artery bypass grafting," <i>Eur. J. Clin. Chem. Clin. Biochem.</i> 32:543-547 (1994).	
	C191	Maiuri <i>et al.</i> , "Serum and cerebrospinal fluid enzymes in subarachnoid haemorrhage," <i>Neurol. Res.</i> , 11:6-8 (1989).	
	C192	Mallamaci, F. <i>et al.</i> , "Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients," <i>Kidney Int.</i> 62(5):1884-1890 (Nov 2002).	
	C193	Manicourt <i>et al.</i> , "Serum levels of collagenase, stromelysin-1, and TIMP-1," <i>Arthritis Rheum.</i> , 37:1774-1783 (1994).	
	C194	Manten, A. <i>et al.</i> , "Procoagulant and proinflammatory activity in acute coronary syndromes," <i>Cardiovasc. Res.</i> 40:389-395 (1998).	
	C195	Martens <i>et al.</i> , "Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia," <i>Stroke</i> , 29: 2363-2366 (1998).	
	C196	Matsuda, H. <i>et al.</i> , "A sandwich enzyme immunoassay for human muscle-specific β -enolase and its application for the determination of skeletal muscle injury," <i>Forensic Sci. Int.</i> 99:197-208 (1999).	
	C197	Matsumori <i>et al.</i> , "Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction," <i>J. Mol. Cell. Cardiol.</i> , 29:419-423 (1997).	
	C198	Mehta, J. <i>et al.</i> , "Neutrophil function in ischemic heart disease," <i>Circulation</i> 79:549-556 (1989).	
	C199	Merlini, P.A. <i>et al.</i> , "Persistent activation of coagulation mechanism in unstable angina and myocardial infarction," <i>Circulation</i> 90:61-68 (1994).	
	C200	Michelson, A.D. <i>et al.</i> , "In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function," <i>Proc. Natl. Acad. Sci. U S A.</i> 93:11877-11882 (1996).	
	C201	Missler <i>et al.</i> , "S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke," <i>Stroke</i> 28, 1956-1960 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
Sheet	18	of	28	Attorney Docket Number	071949-5604

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C202	Misumi, K. <i>et al.</i> , "Comparison of plasma tissue factor levels in unstable and stable angina pectoris," <i>Am. J. Cardiol.</i> 81:22-26 (1998).	
	C203	Miwa, K. <i>et al.</i> , "Soluble E-selectin, ICAM-1 and VCAM-1 levels in systemic and coronary circulation in patients with variant angina," <i>Cardiovasc. Res.</i> 36:37-44 (1997).	
	C204	Miyata <i>et al.</i> , "Conformational changes in the A1 domain of von Willebrand factor modulating the interaction with platelet glycoprotein Iba," <i>J. Biol. Chem.</i> 271:9046-9053 (1996).	
	C205	Montalescot <i>et al.</i> , "Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease," <i>Circulation</i> 98:294-299 (1998).	
	C206	Moore <i>et al.</i> , "Collagenase expression in ovarian cancer cell lines," <i>Gynecol. Oncol.</i> 65:78-82 (1997).	
	C207	Mooser, V. <i>et al.</i> , "Effect of cardiopulmonary bypass and heparin on plasma levels of Lp(a) and Apo(a) fragments," <i>Arterioscler. Thromb. Vasc. Biol.</i> 19:1060-1065 (1999).	
	C208	Morgan and Hodge, "Diagnostic evaluation of dyspnea," <i>Am. Fam. Physician</i> 57:711-16 (1998).	
	C209	Morita, T. <i>et al.</i> , "Evaluation of serum S100ao protein in patients with renal cell carcinoma," <i>Nippon Hinyokika Gakkai Zasshi</i> 81:1162-1167 (1990).	
	C210	Mowla <i>et al.</i> , "Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor," <i>J. Biol. Chem.</i> 276: 12660-12666 (2001).	
	C211	Mulrow <i>et al.</i> , "Discriminating causes of dyspnea through clinical examination," <i>J. Gen. Int. Med.</i> 8:383-92 (1993).	
	C212	Mulvihill, N. <i>et al.</i> , "Early temporal expression of soluble cellular adhesion molecules in patients with unstable angina and subendocardial myocardial infarction," <i>Am. J. Cardiol.</i> 83:1265-7, A9 (1999).	
	C213	Mun-Bryce <i>et al.</i> , "Matrix metalloproteinases in cerebrovascular disease," <i>J. Cereb. Blood Flow Metab.</i> 18:1163-1172 (1998).	
	C214	Murawaki, Y. <i>et al.</i> , "Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis," <i>J. Gastroenterol. Hepatol.</i> 14:138-145 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
				Attorney Docket Number	071949-5604
Sheet	19	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C215	Murawaki, Y. <i>et al.</i> , "Clinical usefulness of serum matrixmetalloproteinase-2 concentration in patients with chronic viral liver disease," <i>J. Hepatol.</i> 30:1090-1098 (1999).	
	C216	Musso, P. <i>et al.</i> , "Troponina I cardiaca E troponina T cardiaca nell'angina instabile: incidenza, correlazione, cinetica di rilasciamento e valore prognostico," <i>J. Ital. Cardiol.</i> 26:1013-23 (1996).	
	C217	Nakamura, T. <i>et al.</i> , "Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment," <i>Am. J. Med. Sci.</i> 316:355-360 (1998).	
	C218	Ng and Ilag, "Biomedical applications of protein chips," <i>J. Cell Mol. Med.</i> 6:329-340 (2002).	
	C219	Ni, Z. <i>et al.</i> , "Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia," <i>Kidney Int.</i> 52:195-201 (1997).	
	C220	Niebroj-Dobosz, I., <i>et al.</i> , "Immunochemical analysis of some proteins in cerebrospinal fluid and serum of patients with ischemic strokes," <i>Folia Neuropathol.</i> 32:129-137 (1994).	
	C221	Nishiyama <i>et al.</i> , "Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes," <i>Jpn. Circ. J.</i> 62:710-712 (1998).	
	C222	Nishizawa <i>et al.</i> , "Protein kinase C δ and α are involved in the development of vasospasm after subarachnoid hemorrhage," <i>Eur. J. Pharmacol.</i> 398: 113-119 (2000).	
	C223	Nomura, M. <i>et al.</i> , "Serum β -enolase in acute myocardial infarction," <i>Br. Heart J.</i> 58:29-33 (1987).	
	C224	Nomura, S. <i>et al.</i> , "Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes," <i>Thromb. Haemost.</i> 80:388-392 (1998).	
	C225	Norregaard-Hansen, K. <i>et al.</i> , "Lack of indication of myocardial cell damage after myocardial ischaemia in patients with severe stable angina," <i>Eur. Heart J.</i> 13:188-193 (1992).	
	C226	O'Connor, C.M. <i>et al.</i> , "Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure," <i>Am. J. Cardiol.</i> 83:1345-1349 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
(use as many sheets as necessary)				Attorney Docket Number	071949-5604
Sheet	20	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C227	Ogawa, H. <i>et al.</i> , "Plasma platelet-derived growth factor levels in coronary circulation in unstable angina pectoris," <i>Am. J. Cardiol.</i> 69:453-456 (1992).	
	C228	Ogawa, H. <i>et al.</i> , "Plasma soluble intercellular adhesion molecule-1 levels in coronary circulation in patients with unstable angina," <i>Am. J. Cardiol.</i> 83:38-42 (1999).	
	C229	Ogawa, H. <i>et al.</i> , "Platelet-derived growth factor is released into the coronary circulation after coronary spasm," <i>Coron. Artery Dis.</i> 4:437-442 (1993).	
	C230	Ohtsuka <i>et al.</i> , "Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction," <i>Coron. Artery Dis.</i> 10:221-225 (1999).	
	C231	Otsuki <i>et al.</i> , "Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients," <i>Diabetes</i> 46:2096-2101 (1997).	
	C232	Paganuzzi, M. <i>et al.</i> , "Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma," <i>Chest</i> 119(4):1138-42 (2001).	
	C233	Palfreyman, J.W. <i>et al.</i> , "Radioimmunoassay of serum myelin basic protein and its application to patients with cerebrovascular accident," <i>Clin. Chim. Acta</i> 92:403-409 (1979).	
	C234	Pellegatta, F. <i>et al.</i> , "Soluble E-selectin and intercellular adhesion molecule-1 plasma levels increase during acute myocardial infarction," <i>J. Cardiovasc. Pharmacol.</i> 30:455-460 (1997).	
	C235	Persson <i>et al.</i> , "S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system," <i>Stroke</i> 18:911-918 (1987).	
	C236	Peter, K. <i>et al.</i> , "Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin," <i>Arterioscler. Thromb. Vasc. Biol.</i> 17:505-512 (1997).	
	C237	Pettila <i>et al.</i> , "Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis," <i>Intensive Care Med.</i> 28:1220-25 (2002).	
	C238	Plow, E.F., "Leukocyte elastase release during blood coagulation," <i>J. Clin. Invest.</i> 69:564-572 (1982).	
	C239	Plow, E.F. and Plescia, J., "Neutrophil secretion during blood coagulation: evidence for a prekallikrein independent pathway," <i>Thromb. Haemost.</i> 59:360-363 (1988).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
(use as many sheets as necessary)				Attorney Docket Number	071949-5604
Sheet	21	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C240	Polin et al., "Detection of soluble E-selectin, ICAM-1, VCAM-1, and L-selectin in the cerebrospinal fluid of patients after subarachnoid hemorrhage," <i>J. Neurosurg.</i> 89:559-567 (1998).	
	C241	Prickett et al., "Identification of amino-terminal pro-C-type natriuretic peptide in human plasma," <i>Biochem. Biophys. Res. Commun.</i> 286:513-517 (2001).	
	C242	Quinn et al., "Mapping of antigenic sites in human neuron-specific enolase by expression subcloning," <i>Clin. Chem.</i> 40: 790-795 (1994).	
	C243	Rabitzsch, G. et al., "Immunoinhibition assay of the serum activity of human glycogen isophosphorylase BB in the diagnosis of the acutemyocardial ischaemia," <i>Biomed. Biochim. Acta</i> 46:S584-S588 (1987).	
	C244	Rabitzsch, G. et al., "Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury," <i>Clin. Chem.</i> 41:966-978 (1995).	
	C245	Rabitzsch, G. et al., "Isoenzyme BB of glycogen phosphorylase b and myocardial infarction," <i>Lancet</i> 341:1032-1033 (1993).	
	C246	Ray et al., "Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy," <i>Cancer Detect. Prev.</i> 22: 293-304 (1998).	
	C247	Reeves, D., "Tryptase," <i>Immunology HAPS</i> (June 1998).	
	C248	Robey et al., "Binding of C-reactive protein to chromatin and nucleosome core particles," <i>J. Biol. Chem.</i> 259:7311-7316 (1984).	
	C249	Romanic et al., "Matrix metalloproteinase expression increases after cerebral focal ischemia in rats," <i>Stroke</i> 29:1020-1030 (1998).	
	C250	Rosenberg, "Matrix metalloproteinases in brain injury," <i>J. Neurotrauma</i> 12:833-842 (1995).	
	C251	Rossi et al., "Natriuretic peptide levels in atrial fibrillation," <i>Journal of the American College of Cardiology</i> 35: 1256-62 (2000).	
	C252	Rossi, E. et al., "Increased plasma levels of platelet-derived growth factor(PDGF-BB + PDGF-AB) in patients with never-treated mild essential hypertension," <i>Am. J. Hypertens.</i> 11:1239-1243 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
Group Art Unit		1641			
Examiner Name		Jung			
Attorney Docket Number		071949-5604			

(use as many sheets as necessary)

Sheet	22	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C253	Rubattu et al., "The gene encoding atrial natriuretic peptide and the risk of human stroke," <i>Circulation</i> 100:1722-1726 (1999).	
	C254	Rucinski et al., "Clearance of human platelet factor 4 by liver and kidney: its alteration by heparin," <i>Am. J. Physiol.</i> 251: H800-H807 (1986).	
	C255	Sagnella, G.A., "Measurement and significance of circulating natriuretic peptides in cardiovascular disease," <i>Clinical Science</i> 95:519-29 (1998).	
	C256	Sakamaki, F. et al., "Soluble form of P-selectin in plasma is elevated in acute lung injury," <i>A. J. Respir. Crit. Care Med.</i> 151:1821-1826 (1995).	
	C257	Sakata, K. et al., "Characteristics of vasospastic angina with exercised-induced ischemia—analysis of parameters of hemostasis and fibrinolysis—," <i>Jpn. Circ. J.</i> 60:277-284 (1996).	
	C258	Saraste A., "Morphologic criteria and detection of apoptosis," <i>Herz.</i> 24:189-195 (1999).	
	C259	Sasagawa, T. et al., "The significance of plasma lysophospholipids in patients with renal failure on hemodialysis," <i>J. Nutr. Sci. Vitaminol.</i> (Tokyo) 44:809-818 (1998).	
	C260	Sawicki, G. et al., "Localization and translocation of MMP-2 during aggregation of human platelets," <i>Thromb. Haemost.</i> 80:836-839 (1998).	
	C261	Schabiltz et al., "Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats," <i>J. Cereb. Blood Flow Metab.</i> 17: 500-506 (1997).	
	C262	Schaller et al., "Elevated levels of head activator in human brain tumors and in serum of patients with brain and other neurally derived tumors," <i>J. Neuro. Oncol.</i> 6:251-258 (1988).	
	C263	Schins and Borm, "Epidermological evaluation or release of monocyte TNF- α as an exposure and effect marker in pneumoconiosis: a five year follow up study of coal workers," <i>Occup. Environ. Med.</i> 52:441-50 (1995).	
	C264	Schwab et al., "Plasma insulin-like growth factor I and IGF binding protein 3 levels in patients with acute cerebral ischemic injury," <i>Stroke</i> 28:1744-1748 (1997).	
	C265	Schwartz et al., "Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis," <i>N. Engl. J. Med.</i> 316:1622-26 (1987).	
	C266	Seki et al., "Sustained activation of blood coagulation in patients with cerebral thrombosis," <i>A. J. Hematol.</i> 50: 155-160 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
				Examiner Name	Jung
				Attorney Docket Number	071949-5604
Sheet	23	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C267	Seki et al., "Plasma levels of thrombomodulin and lipoprotein (a) in patients with cerebral thrombosis," <i>Blood Coagul. Fibrinolysis</i> 8:391-396 (1997).	
	C268	Seymour, L. et al., "Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer," <i>Breast Cancer Res. Treat.</i> 26:247-252 (1993).	
	C269	Shamsham and Mitchell, "Essentials of the diagnosis of heart failure," <i>Am. Fam. Physician</i> 61:1319-28 (2000).	
	C270	Shibata, M. et al., "Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 Levels in coronary reperfusion therapy for patients with acute myocardial infarction," <i>Angiology</i> 50:573-582 (1999).	
	C271	Shimomura, H. et al., "Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction," <i>Am. J. Cardiol.</i> 81:397-400 (1998).	
	C272	Shyu et al., "Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke," <i>J. Neurol.</i> 244:90-93 (1997).	
	C273	Siess, W., "Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 96, 6931-6936 (1999).	
	C274	Sixma et al., "Von Willebrand factor and the blood vessel wall," <i>Mayo Clin. Proc.</i> 66:628-633 (1991).	
	C275	Skogseid et al., "Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage," <i>Acta Neurochir (Wein)</i> , 115: 106-111 (1992).	
	C276	Sobel, M. et al., "Circulating platelet products in unstable angina pectoris," <i>Circulation</i> 63:300-306 (1981).	
	C277	Soejima, H. et al., "Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina," <i>Circulation</i> 99:2908-2913 (1999).	
	C278	Soejima, H. et al., "Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction," <i>J. Am. Coll. Cardiol.</i> 34:983-988 (1999).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
Group Art Unit		1641			
Examiner Name		Jung			
Attorney Docket Number		071949-5604			

(use as many sheets as necessary)

Sheet	24	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C279	Sorbi et al., "Elevated levels of 92-kd type IV collagenase (Matrix metalloproteinase 9) in giant cell arteritis," <i>Arthritis Rheum.</i> 39:1747-1753 (1996).	
	C280	Sorkness et al., "Evaluation of serum eosinophil cationic protein as a predictive marker for asthma exacerbation in patients with persistent disease," <i>Clin. Exp. Allergy</i> 32:1355-59 (2002).	
	C281	Soufer et al., "Intact systolic left ventricular function in clinical congestive heart failure," <i>Am. J. Cardiol.</i> 55:1032-6 (1985).	
	C282	Squadrito, F. et al., "Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction," <i>Inflamm. Res.</i> 45:14-19 (1996).	
	C283	Steiner et al., "Increased levels of soluble adhesion molecules in Type 2 (Non-insulin dependent) diabetes mellitus are independent of glycaemic control," <i>Thromb. Haemost.</i> 72:979-984 (1994).	
	C284	Stockman et al., "Secondary structure and topology of interleukin-1 receptor antagonist protein determined by heteronuclear three-dimensional NMR spectroscopy," <i>Biochemistry</i> 31:5237-5245 (1992).	
	C285	Suefuji, H. et al., "Increased plasma tissue factor levels in acute myocardial infarction," <i>Am. Heart J.</i> 134:253-259 (1997).	
	C286	Suga et al., "Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases," <i>Eur. Respir. J.</i> 14:376-382 (1999).	
	C287	Switaiska et al., "Radioimmunoassay of human platelet thrombospondin: different patterns of thrombospondin and β -thromboglobulin antigen secretion and clearance from the circulation," <i>J. Lab. Clin. Med.</i> 106: 690-700 (1985).	
	C288	Taira et al., "Serum B12 tryptase level as a marker of allergic airway inflammation in asthma," <i>J. Asthma</i> 39:315-22 (2002).	
	C289	Takahashi et al., "Tissue factor in plasma of patients with disseminated intravascular coagulation," <i>Am. J. Hematol.</i> 46:333-337 (1994).	
	C290	Takeda, I. et al., "Soluble P-selectin in the plasma of patients with connective tissue diseases," <i>Int. Arch. Allergy Immunol.</i> 105:128-134 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
Group Art Unit		1641			
Examiner Name		Jung			
Attorney Docket Number		071949-5604			

(use as many sheets as necessary)

Sheet	25	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C291	Tanaka, M. and Suzuki, A., "Hemostatic abnormalities in acute myocardial infarction as detected by specific blood markers, <i>Thromb. Res.</i> 76:289-98 (1994).	
	C292	Tanaka, T. <i>et al.</i> , "Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction," <i>Clin. Biochem.</i> 24:195-201 (1991).	
	C293	Tanasijevic, M.J., "The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease," <i>et al.</i> , <i>Clin. Cardiol.</i> 22:13-16 (1999).	
	C294	Tateyama <i>et al.</i> , "Concentrations and molecular forms of human brain natriuretic peptide in plasma," <i>Biochem. Biophys. Res. Commun.</i> 185:760-7 (1992).	
	C295	Tenaglia, A.N. <i>et al.</i> , "Levels of expression of P-selectin, E-selectin, and intercellular adhesion molecule-1 in coronary atherectomy specimens from patients with stable and unstable angina pectoris," <i>Am. J. Cardiol.</i> 79:742-747 (1997).	
	C296	Theroux, P. <i>et al.</i> , "Febrinopeptide A and platelet factor levels in unstable angina pectoris," <i>Circulation</i> 75:156-162 (1987).	
	C297	Thomas <i>et al.</i> , "Serum myelin basic protein, clinical responsiveness, and outcome of severe head injury," <i>Acta Neurochir. Suppl.</i> 28: 93-95 (1979).	
	C298	Thygesen, K. <i>et al.</i> , "Creatine kinase and creatine kinase B-subunit in stable and unstable angina pectoris," <i>Eur. J. Clin. Invest.</i> 16:1-4 (1986).	
	C299	Tietz Textbook of Clinical Chemistry, 2nd edition, Carl Burtis and Edward Ashwood eds., W.B. Saunders and Company, p. 485-507.	
	C300	Tohgi <i>et al.</i> , "Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism," <i>Stroke</i> 21: 1663-1667 (1990).	
	C301	Tomoda, H. and Aoki, N., "Plasma soluble P-selectin in acute myocardial infarction: effects of coronary recanalization therapy," <i>Angiology</i> 49:807-813 (1998).	
	C302	Tousoulis <i>et al.</i> , "Von Willebrand factor in patients evolving Q-wave versus non-Q-wave acute myocardial infarction," <i>Int. J. Cardiol.</i> 56:259-262 (1996).	
	C303	Trotter <i>et al.</i> , "Immunoreactive myelin proteolipid protein-like activity in cerebrospinal fluid and serum of neurologically impaired patients," <i>Ann. Neurol.</i> , 14: 554-558 (1983).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
		Kenneth F. Buechler			
				Group Art Unit	
				1641	
				Examiner Name	
				Jung	
				Attorney Docket Number	
				071949-5604	

(use as many sheets as necessary)

Sheet	26	of	28
-------	----	----	----

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C304	Tsuji, R. <i>et al.</i> , "Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction," <i>Int. J. Cardiol.</i> 41:209-217 (1993).	
	C305	Uchiyama <i>et al.</i> , "Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke," <i>Semin. Thromb. Hemost.</i> 23: 535-541 (1997).	
	C306	Ushiyama, S. <i>et al.</i> , "Structural and functional characterization of monomeric soluble P-selectin and comparison with membrane P-selectin," <i>J. Biol. Chem.</i> 268:15229-15237 (1993).	
	C307	Usui, A. <i>et al.</i> , "β-Enolase in blood plasma during open heart surgery," <i>Cardiovasc. Res.</i> 23:737-740 (1989).	
	C308	Usui, A. <i>et al.</i> , "Neural tissue-related proteins (NSE, G ₀ α, 28-kDa calbindin-D, S100b and CK-BB) in serum and cerebrospinal fluid after cardiac arrest," <i>J. Neurol. Sci.</i> 123:134-139 (1994).	
	C309	Usui, A. <i>et al.</i> , "S-100a ₀ protein in blood and urine during open-heart surgery," <i>Clin. Chem.</i> 35:1942-1944 (1989).	
	C310	Usui, A. <i>et al.</i> , "S-100a ₀ protein in serum during acute myocardial infarction," <i>Clin. Chem.</i> 36:639-641 (1990).	
	C311	van den Dorpel, M.A. <i>et al.</i> , "Low-density lipoprotein oxidation is increased in kidney transplant recipients," <i>Transpl. Int.</i> 9 Suppl. 1:S54-S57 (1996).	
	C312	Van Nieuwenhoven, F.A. <i>et al.</i> , "Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein," <i>Circulation</i> 92:2848-2854 (1995).	
	C313	Veerkamp, J.H. and Maatman, R.G., "Cytoplasmic fatty acid-binding proteins: their structure and genes," <i>Prog. Lipid Res.</i> 34:17-52 (1995).	
	C314	Venge, "Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma," <i>Clinical and experimental allergy</i> , 23 (2):3-7 (1993).	
	C315	Viera <i>et al.</i> , "Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRF1," <i>Proc. Natl. Acad. Sci. USA</i> 88:1172-76 (1991).	
	C316	Virchow <i>et al.</i> , "Sputum ECP levels correlate with parameters of airflow obstruction," <i>Am. Rev. Respir. Dis.</i> 146:604-6 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	
				10/728,067	
				Filing Date	
				12/03/2003	
				First Named Inventor	
				Kenneth F. Buechler	
				Group Art Unit	
				1641	
				Examiner Name	
				Jung	
				Attorney Docket Number	
				071949-5604	
(use as many sheets as necessary)					
Sheet	27	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C317	Wallace, J.M. <i>et al.</i> , "The assessment of platelet derived growth factor concentration in post myocardial infarction and stable angina patients," <i>Ann. Clin. Biochem.</i> 35:236-241 (1998).	
	C318	Ward <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> 341:544-546 (1989).	
	C319	Whicher <i>et al.</i> , "Procalcitonin as an acute phase marker," <i>Ann. Clin. Biochem.</i> 38: 483-93 (2001).	
	C320	Wilkins <i>et al.</i> , "The natriuretic-peptide family," <i>Lancet</i> , 349:1307-1310 (1997).	
	C321	Wilson <i>et al.</i> , "Simplified conjugation chemistry for coupling peptides to F(ab') fragments: autologous red cell agglutination assay for HIV-1 antibodies," <i>J. Immunol. Methods</i> 175:267-273 (1994).	
	C322	Winnikes <i>et al.</i> , "Head activator as a potential serum marker for brain tumor analysis," <i>Eur. J. Cancer</i> 28:421-424 (1992).	
	C323	Woertgen <i>et al.</i> , "Comparison of serial S-100 and NSE serum measurements after severe head injury," <i>Acta Neurochir (Wien)</i> 139: 1161-1165 (1997).	
	C324	Xu, Y. <i>et al.</i> , "Lysophosphatidic Acid as a potential biomarker for ovarian and other gynecologic cancers," <i>JAMA</i> 280:719-723 (1998).	
	C325	Yamane <i>et al.</i> , "Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis," <i>J. Rheumatol.</i> 27:930-4 (2000).	
	C326	Yamazaki <i>et al.</i> , "Alterations of haemostatic markers in various subtypes and phases of stroke," <i>Blood Coagul. Fibrinolysis</i> 4:707-712 (1993).	
	C327	Yap <i>et al.</i> , "Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi," <i>Br. J. Pharmacol.</i> 129:170-6 (2000).	
	C328	Yarmush <i>et al.</i> , "Coupling of antibody-binding fragments to solid-phase supports: site-directed binding of F(ab') ₂ fragments," <i>J. Biochem. Biophys. Methods</i> 25:285-297 (1992).	
	C329	Yazdani, S. <i>et al.</i> , "Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina," <i>J Am Coll Cardiol</i> 30:1284-1287 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/728,067
				Filing Date	12/03/2003
				First Named Inventor	Kenneth F. Buechler
				Group Art Unit	1641
Examiner Name	Jung				
Attorney Docket Number	071949-5604				
Sheet	28	of	28		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C330	Yoneda et al., "Identification of a novel adenylate kinase system in the brain: Cloning of the fourth adenylate kinase," <i>Mol. Brain Res.</i> 62:187-195 (1998).	
	C331	Yoshimoto, K. et al., "Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction," <i>Heart Vessels</i> 10:304-309 (1995).	
	C332	Yoshimura et al., "Human monocyte chemoattractant protein-1 (MCP-1)," <i>FEBS Lett.</i> 244:487-493 (1989).	
	C333	Yoshitomi et al., "Plasma levels of adrenomedullin in patients with acute myocardial infarction," <i>Clin. Sci.</i> 94:135-9 (1998).	
	C334	Yukioka et al., "Plasma procalcitonin in sepsis and organ failure," <i>Ann. Acad. Med. Singapore</i> 30:528-31 (2001).	
	C335	Zucker et al., "Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity," <i>J. Rheumatol.</i> 26:78-80 (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.